Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease
Christopher B Forsyth, Kathleen M Shannon, Jeffrey H Kordower, Robin M Voigt, Maliha Shaikh, Jean A Jaglin, Jacob D Estes, Hemraj B Dodiya, Ali Keshavarzian, Christopher B Forsyth, Kathleen M Shannon, Jeffrey H Kordower, Robin M Voigt, Maliha Shaikh, Jean A Jaglin, Jacob D Estes, Hemraj B Dodiya, Ali Keshavarzian
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder of aging. The pathological hallmark of PD is neuronal inclusions termed Lewy bodies whose main component is alpha-synuclein protein. The finding of these Lewy bodies in the intestinal enteric nerves led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. One potential mechanism for environmental toxin(s) and proinflammatory luminal products to gain access to mucosal neuronal tissue and promote oxidative stress is compromised intestinal barrier integrity. However, the role of intestinal permeability in PD has never been tested. We hypothesized that PD subjects might exhibit increased intestinal permeability to proinflammatory bacterial products in the intestine. To test our hypothesis we evaluated intestinal permeability in subjects newly diagnosed with PD and compared their values to healthy subjects. In addition, we obtained intestinal biopsies from both groups and used immunohistochemistry to assess bacterial translocation, nitrotyrosine (oxidative stress), and alpha-synuclein. We also evaluated serum markers of endotoxin exposure including LPS binding protein (LBP). Our data show that our PD subjects exhibit significantly greater intestinal permeability (gut leakiness) than controls. In addition, this intestinal hyperpermeability significantly correlated with increased intestinal mucosa staining for E. coli bacteria, nitrotyrosine, and alpha-synuclein as well as serum LBP levels in PD subjects. These data represent not only the first demonstration of abnormal intestinal permeability in PD subjects but also the first correlation of increased intestinal permeability in PD with intestinal alpha-synuclein (the hallmark of PD), as well as staining for gram negative bacteria and tissue oxidative stress. Our study may thus shed new light on PD pathogenesis as well as provide a new method for earlier diagnosis of PD and suggests potential therapeutic targets in PD subjects.
Trial registration: Clinicaltrials.gov NCT01155492.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055–2066.
- Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–386.
- Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry. 2010;81:1093–1098.
- Shults CW. Lewy bodies. Proc Natl Acad Sci U S A. 2006;103:1661–1668.
- Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916–1925.
- Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet. 2007;16 Spec No. 2:R183–194.
- Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, et al. The second brain and Parkinson's disease. Eur J Neurosci. 2009;30:735–741.
- Savidge TC, Sofroniew MV, Neunlist M. Starring roles for astroglia in barrier pathologies of gut and brain. Lab Invest. 2007;87:731–736.
- Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–1359.
- Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14.
- Menard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol. 2010;3:247–259.
- John LJ, Fromm M, Schulzke JD. Epithelial barriers in intestinal inflammation. Antioxid Redox Signal 2011
- Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol. 2003;18:479–497.
- Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517–536.
- Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33:599–614.
- Gutsmann T, Muller M, Carroll SF, MacKenzie RC, Wiese A, et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun. 2001;69:6942–6950.
- Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 1995;270:10482–10488.
- Minter RM, Bi X, Ben-Josef G, Wang T, Hu B, et al. LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction. Am J Physiol Gastrointest Liver Physiol. 2009;296:G45–54.
- Shannon K, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, jaglin JA, Kordower JH. Alpha-synuclein in Colonic Submucosa in Early Untreated Parkinson Disease. Movement Disorders. 2011 In press.
- Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp Neurol. 2009;218:154–161.
- Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology. 1987;37:1253–1255.
- Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology. 1984;87:848–856.
- Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 1988;76:217–221.
- Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 1990;79:581–583.
- Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997;38(Suppl 2):2–7.
- Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, et al. Pathological lesions in colonic biopsies during Parkinson's disease. Gut. 2008;57:1741–1743.
- Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One. 2010;5:e12728.
- Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience. 2008;153:733–750.
- Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2011
- Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8:382–397.
- Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S200–204.
- McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004;1035:104–116.
- Niehaus I, Lange JH. Endotoxin: is it an environmental factor in the cause of Parkinson's disease? Occup Environ Med. 2003;60:378.
- Qin L, Wu X, Block ML, Liu Y, Breese GR, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453–462.
- Wang S, Yan JY, Lo YK, Carvey PM, Ling Z. Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Res. 2009;1265:196–204.
- Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007;150:963–976.
- Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005;11:225–229.
- Keck S, Muller I, Fejer G, Savic I, Tchaptchet S, et al. Absence of TRIF Signaling in Lipopolysaccharide-Stimulated Murine Mast Cells. J Immunol. 2011;186:5478–5488.
- Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000;20:6309–6316.
- Gao HM, Zhang F, Zhou H, Kam W, Wilson B, et al. Neuroinflammation and alpha-Synuclein Dysfunction Potentiate Each Other Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson's Disease. Environ Health Perspect 2011
- Cirillo C, Sarnelli G, Esposito G, Grosso M, Petruzzelli R, et al. Increased mucosal nitric oxide production in ulcerative colitis is mediated in part by the enteroglial-derived S100B protein. Neurogastroenterol Motil. 2009;21:1209-e1112.
- Murakami M, Ohta T, Ito S. Lipopolysaccharides enhance the action of bradykinin in enteric neurons via secretion of interleukin-1beta from enteric glial cells. J Neurosci Res. 2009;87:2095–2104.
- Zhang R, Miller RG, Gascon R, Champion S, Katz J, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2009;206:121–124.
- Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett. 2008;29:117–124.
- Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, et al. Low-grade endotoxemia in patients with severe autism. Neurosci Lett. 2010;471:162–165.
- Davies KN, King D, Billington D, Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J. 1996;72:164–167.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
- McOmber ME, Ou CN, Shulman RJ. Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults. J Pediatr Gastroenterol Nutr. 2010;50:269–275.
- Farhadi A, Keshavarzian A, Fields JZ, Sheikh M, Banan A. Resolution of common dietary sugars from probe sugars for test of intestinal permeability using capillary column gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;836:63–68.
- Farhadi A, Keshavarzian A, Holmes EW, Fields J, Zhang L, et al. Gas chromatographic method for detection of urinary sucralose: application to the assessment of intestinal permeability. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:145–154.
- Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6
Source: PubMed